TP53 and neoplasm: At the age of 6 years, the patient was recruited for a TP53 mutation prevalence study, which was offered to all patients diagnosed or treated for paediatric tumours of the LFS cancer spectrum at Hospital de Clínicas de Porto Alegre from 1998 to 2010 (IRB# 08022).